Literature DB >> 36251153

Hace1 overexpression mitigates myocardial hypoxia/reoxygenation injury via the effects on Keap1/Nrf2 pathway.

Ting-Yan Chen1, Shi-Kang Zheng2.   

Abstract

HECT domain and ankyrin repeat containing E3 ubiquitin protein ligase 1 (Hace1) is a crucial mediator of multiple pathological disorders. However, there are few studies regarding the role of Hace1 in myocardial ischemia/reperfusion injury. Here, we studied the functional role of Hace1 on myocardial ischemia/reperfusion injury using hypoxia/reoxygenation (H/R)-injured cardiac cells in vitro. Reduced levels of Hace1 were observed in H/R-exposed cardiac cells. Hace1-overexpressed cardiac cells were resistant to H/R injuries with reduced apoptosis, lowered oxidative stress, and a suppressed inflammatory response. Subsequent analysis revealed that Hace1 overexpression enhanced the activation of nuclear translocation of nuclear factor (erythroid-derived 2)-like 2 (Nrf2) and increased the transcriptional activity of Nrf2 in H/R-exposed cardiac cells. The knockout of kelch-like ECH-associated protein 1 (Keap1) diminished the regulatory role of Hace1 on Nrf2 activation. Additionally, inhibiting Nrf2 reversed Hace1-elicited cardioprotective effects in H/R-injured cardiac cells. In short, these data demonstrated that Hace1 overexpression mitigated myocardial H/R injury by enhancing the Nrf2 pathway via Keap1. This work underlines a possible role of Hace1 in myocardial ischemia/reperfusion injury and suggests Hace1 as a candidate target for exploiting cardioprotective therapy.
© 2022. The Society for In Vitro Biology.

Entities:  

Keywords:  Hace1; Keap1; Myocardial ischemia/reperfusion injury; Nrf2; Oxidative stress

Year:  2022        PMID: 36251153     DOI: 10.1007/s11626-022-00725-3

Source DB:  PubMed          Journal:  In Vitro Cell Dev Biol Anim        ISSN: 1071-2690            Impact factor:   2.723


  1 in total

1.  Methylation of HACE1 in gastric carcinoma.

Authors:  Makiko Sakata; Yo-Hei Kitamura; Kazuma Sakuraba; Tetsuhiro Goto; Hiroki Mizukami; Mitsuo Saito; Kazuyoshi Ishibashi; Gaku Kigawa; Hiroshi Nemoto; Yutaka Sanada; Kenji Hibi
Journal:  Anticancer Res       Date:  2009-06       Impact factor: 2.480

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.